

Patrizia Ferroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7122596/publications.pdf>

Version: 2024-02-01

174
papers

4,972
citations

87723

38
h-index

128067

60
g-index

175
all docs

175
docs citations

175
times ranked

7766
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. <i>Cancers</i> , 2021, 13, 1556.	1.7	1
2	Towards the Interpretability of Machine Learning Predictions for Medical Applications Targeting Personalised Therapies: A Cancer Case Survey. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4394.	1.8	33
3	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. <i>Current Medicinal Chemistry</i> , 2021, 28, 3158-3172.	1.2	1
4	Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients – The Importance of Tissue/Plasma Discordant Cases. <i>Journal of Clinical Medicine</i> , 2021, 10, 87.	1.0	10
5	Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. <i>Cancers</i> , 2020, 12, 1167.	1.7	5
6	Machine learning approach to predict medication overuse in migraine patients. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1487-1496.	1.9	23
7	Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. <i>Cancers</i> , 2019, 11, 95.	1.7	33
8	Precision medicine in the ageing world: The role of biospecimen sciences. <i>International Journal of Biological Markers</i> , 2019, 34, 3-5.	0.7	3
9	Breast Cancer Prognosis Using a Machine Learning Approach. <i>Cancers</i> , 2019, 11, 328.	1.7	101
10	Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. <i>Neurological Sciences</i> , 2019, 40, 1717-1724.	0.9	9
11	Genetic bases of the nutritional approach to migraine. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 2308-2320.	5.4	4
12	Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. <i>Current Medicinal Chemistry</i> , 2019, 26, 6191-6206.	1.2	25
13	Meet Our Section Editor. <i>Current Medicinal Chemistry</i> , 2019, 26, 361-361.	1.2	0
14	Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1144-1183.	2.5	27
15	Artificial intelligence for cancer-associated thrombosis risk assessment. <i>Lancet Haematology</i> , 2018, 5, e391.	2.2	11
16	Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 4705-4712.	0.5	16
17	RISK: A Random Optimization Interactive System Based on Kernel Learning for Predicting Breast Cancer Disease Progression. <i>Lecture Notes in Computer Science</i> , 2017, , 189-196.	1.0	4
18	The role of anti-CGRP antibodies in the pathophysiology of primary headaches. <i>Neurological Sciences</i> , 2017, 38, 31-35.	0.9	22

#	ARTICLE	IF	CITATIONS
19	Procoagulant imbalance in premenopausal women with chronic migraine. <i>Neurology</i> , 2017, 89, 1525-1527.	1.5	8
20	Oxidant stress as a major determinant of platelet activation in invasive breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 696-704.	2.3	24
21	Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients. <i>Medical Decision Making</i> , 2017, 37, 234-242.	1.2	63
22	Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. <i>Journal of Pain Research</i> , 2017, Volume 10, 2319-2329.	0.8	27
23	Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. <i>Disease Markers</i> , 2017, 2017, 1-7.	0.6	49
24	Gender Differences in Cancer-associated Venous Thromboembolism. <i>Current Medicinal Chemistry</i> , 2017, 24, 2589-2601.	1.2	9
25	Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 15, 3-16.	0.4	12
26	Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 5187.	1.4	6
27	VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. <i>Thrombosis and Haemostasis</i> , 2016, 115, 143-151.	1.8	13
28	Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. <i>Cancer Biomarkers</i> , 2016, 17, 335-345.	0.8	13
29	Insulin resistance as a predictor of venous thromboembolism in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, L25-L28.	1.6	9
30	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 783-796.	1.6	31
31	Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. <i>European Journal of Internal Medicine</i> , 2016, 33, 74-80.	1.0	11
32	Low-grade endotoxemia and clotting activation in the early phase of pneumonia. <i>Respirology</i> , 2016, 21, 1465-1471.	1.3	29
33	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1993-2005.	0.5	96
34	Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. <i>Oncologist</i> , 2016, 21, 1041-1049.	1.9	49
35	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. <i>Oncolmmunology</i> , 2016, 5, e1188243.	2.1	26
36	VEGF and VTE Risk in Cancer Patients—Letter. <i>Clinical Cancer Research</i> , 2016, 22, 1295-1295.	3.2	0

#	ARTICLE	IF	CITATIONS
37	Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2016, 15, 187-203.	0.2	9
38	Prognostic value of glycated hemoglobin in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 9984.	1.4	14
39	Abstract 1403: Correlations between overall survival and patient regulatory T-cell levels at initiation of Folfiri therapy in colorectal cancer. , 2016, ,		0
40	Functional impairment of activated protein C in breast cancer - relationship to survival outcomes. <i>American Journal of Cancer Research</i> , 2016, 6, 1450-7.	1.4	1
41	Look beyond Catechol-O-Methyltransferase genotype for catecholamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study. <i>Journal of Headache and Pain</i> , 2015, 16, 520.	2.5	16
42	Sample PREanalytical Code for labeling of biospecimens: an analysis of specimen labeling protocols. <i>Journal of Biorepository Science for Applied Medicine</i> , 2015, , 15.	0.2	0
43	DNA fingerprinting for sample authentication in biobanking: recent perspectives. <i>Journal of Biorepository Science for Applied Medicine</i> , 2015, , 35.	0.2	1
44	Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-10.	1.9	63
45	Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. <i>International Journal of Cancer</i> , 2015, 136, 1234-1240.	2.3	60
46	Is <i>SOD2</i> Ala16Val Polymorphism Associated with Migraine with Aura Phenotype?. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 275-279.	2.5	22
47	Impact of <i>VEGF</i> gene polymorphisms in elderly cancer patients: clinical outcome and toxicity. <i>Pharmacogenomics</i> , 2015, 16, 61-78.	0.6	12
48	Platelet Function: the Janus face of haemostasis in cirrhosis. <i>Thrombosis Research</i> , 2015, 135, 1224-1225.	0.8	2
49	Progesterone Receptor Gene (PROGINS) Polymorphism Correlates with Late Onset of Migraine. <i>DNA and Cell Biology</i> , 2015, 34, 208-212.	0.9	13
50	Obesity and colorectal cancer: Role of adipokines in tumor initiation and progression. <i>World Journal of Gastroenterology</i> , 2014, 20, 5177.	1.4	157
51	Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. <i>Pharmacogenomics</i> , 2014, 15, 2063-2082.	0.6	37
52	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. <i>Haematologica</i> , 2014, 99, 1638-1644.	1.7	20
53	Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy. <i>Oncologist</i> , 2014, 19, 562-567.	1.9	8
54	Association between migraine and <i>ACE</i> gene (insertion/deletion) polymorphism: the BioBIM study. <i>Pharmacogenomics</i> , 2014, 15, 147-155.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Clinical models and biochemical predictors of VTE in lung cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 771-789.	2.7	13
56	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	65
57	Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2049-2053.	1.9	8
58	Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. <i>Medical Oncology</i> , 2014, 31, 166.	1.2	43
59	Diagnostic Procedures for Paraffin-Embedded Tissues Analysis in Pharmacogenomic Studies. <i>Methods in Molecular Biology</i> , 2014, 1175, 45-65.	0.4	3
60	Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). <i>Neurological Sciences</i> , 2013, 34, 1659-1663.	0.9	14
61	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). <i>Medical Oncology</i> , 2013, 30, 743.	1.2	20
62	Research Highlights: Highlights from the latest articles in stroke pharmacogenomics. <i>Pharmacogenomics</i> , 2013, 14, 13-16.	0.6	1
63	TNF- α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 2571-2575.	0.6	16
64	Impact of chemotherapy on activated protein C-dependent thrombin generation Association with VTE occurrence. <i>International Journal of Cancer</i> , 2013, 133, 1253-1258.	2.3	26
65	Increased Risk of Chemotherapy-Associated Venous Thromboembolism in Elderly Patients with Cancer. <i>Rejuvenation Research</i> , 2013, 16, 224-231.	0.9	22
66	Aging: an important risk factor in chemotherapy-associated vascular diseases. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 899-901.	1.1	4
67	Impact of chemotherapy on venous thromboembolism: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , 2013, 98, e153-e154.	1.7	7
68	An importance of identification of double variant methylenetetrahydrofolate reductase gene C677T and A1298C in cis configuration for pharmacogenetic studies. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 784-786.	0.5	4
69	A Reliable and Reproducible Technique for DNA Fingerprinting in Biorepositories: A Pilot Study from BioBIM. <i>International Journal of Biological Markers</i> , 2013, 28, 398-404.	0.7	5
70	Pleiotropic Effects of PPAR γ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2013, 11, 338-351.	0.8	10
71	Obesity-Driven Inflammation and Colorectal Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 5837-5853.	1.2	35
72	Factor Seven Activating Protease Activity Levels in Women With Recurrent Pregnancy Loss. <i>Reproductive Sciences</i> , 2012, 19, 317-321.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies. <i>Current Vascular Pharmacology</i> , 2012, 10, 479-493.	0.8	26
74	SPRECware: Software Tools for Standard PREanalytical Code (SPREC) Labeling – Effective Exchange and Search of Stored Biospecimens. <i>International Journal of Biological Markers</i> , 2012, 27, 272-279.	0.7	19
75	Impact of Preanalytical Handling and Timing for Peripheral Blood Mononuclear Cells Isolation and RNA Studies: The Experience of the Interinstitutional Multidisciplinary BioBank (BioBIM). <i>International Journal of Biological Markers</i> , 2012, 27, 90-98.	0.7	21
76	Biomarkers of platelet activation in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1109-1123.	1.8	81
77	Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study. <i>Supportive Care in Cancer</i> , 2012, 20, 2713-2720.	1.0	7
78	Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 301-309.	1.3	12
79	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 1447-1485.	2.5	57
80	Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2012, 13, 482-487.	1.1	48
81	Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1561-1567.	1.0	18
82	Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral ischemic preconditioning. <i>Pharmacogenomics</i> , 2012, 13, 1741-1757.	0.6	34
83	Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1243-1245.	1.8	2
84	Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. <i>Pharmacogenomics</i> , 2012, 13, 595-613.	0.6	115
85	A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. <i>In Vivo</i> , 2012, 26, 537-47.	0.6	3
86	Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. <i>Clinica Chimica Acta</i> , 2011, 412, 450-454.	0.5	15
87	An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. <i>Thrombosis and Haemostasis</i> , 2011, 105, 931-932.	1.8	20
88	RFID as a New ICT Tool to Monitor Specimen Life Cycle and Quality Control in a Biobank. <i>International Journal of Biological Markers</i> , 2011, 26, 129-135.	0.7	22
89	Platinum-Based Compounds and Risk for Cardiovascular Toxicity in the Elderly: Role of the Antioxidants in Chemoprevention. <i>Rejuvenation Research</i> , 2011, 14, 293-308.	0.9	47
90	Functional impairment in video terminal operators is related to low-grade inflammation. <i>International Archives of Occupational and Environmental Health</i> , 2011, 84, 745-751.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Importance of haplotype analysis in association studies considering VEGF promoter polymorphisms. <i>Clinical Biochemistry</i> , 2011, 44, 748.	0.8	0
92	Anoxia-Reoxygenation Enhances Platelet Thromboxane A ₂ Production via Reactive Oxygen Species-Generated NOX2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1766-1771.	1.1	35
93	VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. <i>Annals of Oncology</i> , 2011, 22, 1928-1929.	0.6	1
94	Preanalytical Procedures for DNA Studies: The Experience of the Interinstitutional Multidisciplinary BioBank (BioBIM). <i>Biopreservation and Biobanking</i> , 2011, 9, 35-45.	0.5	44
95	Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. <i>Current Vascular Pharmacology</i> , 2010, 8, 102-113.	0.8	41
96	Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. <i>Cancer</i> , 2010, 116, 2913-2921.	2.0	32
97	Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. <i>Clinical Biochemistry</i> , 2010, 43, 666-670.	0.8	24
98	VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. <i>Clinical Biochemistry</i> , 2010, 43, 1090-1095.	0.8	17
99	TNFA Gene Promoter Polymorphisms and Susceptibility to Recurrent Pregnancy Loss in Italian Women. <i>Reproductive Sciences</i> , 2010, 17, 659-666.	1.1	21
100	Predictive value of thrombopath determination in women with infertility and pregnancy complications. <i>Clinica Chimica Acta</i> , 2010, 411, 37-42.	0.5	5
101	Determinants of platelet activation in hypertensives with microalbuminuria. <i>Free Radical Biology and Medicine</i> , 2009, 46, 922-927.	1.3	15
102	Soluble P-selectin as a marker of in vivo platelet activation. <i>Clinica Chimica Acta</i> , 2009, 399, 88-91.	0.5	100
103	Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. <i>Thrombosis Research</i> , 2009, 124, 403-408.	0.8	30
104	Chemoprevention of Colonic Cancer Is There a Foreseeable Future?. , 2009, , 77-93.		0
105	Prognostic significance of serum adipokine levels in colorectal cancer patients. <i>Anticancer Research</i> , 2009, 29, 3321-7.	0.5	56
106	Determinants of homocysteine levels in colorectal and breast cancer patients. <i>Anticancer Research</i> , 2009, 29, 4131-8.	0.5	22
107	In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. <i>Clinica Chimica Acta</i> , 2008, 388, 33-37.	0.5	23
108	Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. <i>Clinical Science</i> , 2008, 114, 449-455.	1.8	24

#	ARTICLE	IF	CITATIONS
109	Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2008, 8, 194-202.	0.2	21
110	Birt-Hogg-Dub� (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene. <i>European Journal of Dermatology</i> , 2008, 18, 382-6.	0.3	18
111	Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis. <i>Current Medicinal Chemistry</i> , 2007, 14, 2170-2180.	1.2	66
112	Prognostic significance of interleukin-6 measurement in the diagnosis of acute myocardial infarction in emergency department. <i>Clinica Chimica Acta</i> , 2007, 381, 151-156.	0.5	11
113	Soluble RAGE in type 2 diabetes: Association with oxidative stress. <i>Free Radical Biology and Medicine</i> , 2007, 43, 511-518.	1.3	125
114	CD40/CD40L system and vascular disease. <i>Internal and Emergency Medicine</i> , 2007, 2, 256-268.	1.0	88
115	Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. <i>Anticancer Research</i> , 2007, 27, 483-9.	0.5	41
116	Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. <i>In Vivo</i> , 2007, 21, 147-61.	0.6	47
117	Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. <i>Anticancer Research</i> , 2007, 27, 3147-62.	0.5	31
118	Endothelial dysfunction and oxidative stress in arterial hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 222-233.	1.1	96
119	Protease nexin-1: a regulator of vascular disease?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 320-321.	1.9	3
120	Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. <i>International Journal of Cancer</i> , 2006, 119, 955-960.	2.3	62
121	Prognostic Value of Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Tumor Tissue Content in Colorectal Cancer. <i>Oncology</i> , 2006, 71, 176-184.	0.9	27
122	Low-Density Lipoprotein-Lowering Medication and Platelet Function. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 346-354.	0.5	23
123	Circulating Transforming Growth Factor-� ² 1 Levels in Asymptomatic Carotid Plaques. <i>Stroke</i> , 2005, 36, 525-526.	1.0	3
124	CD40-CD40L interactions in platelet activation. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1011-1012.	1.8	13
125	Microparticles in type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1166-1167.	1.9	11
126	Increased plasminogen activator inhibitor-1 levels in android obesity: correlation with oxidative stress. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1086-1087.	1.9	14

#	ARTICLE	IF	CITATIONS
127	Association between Circulating Adiponectin and Interleukin-10 Levels in Android Obesity: Effects of Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5876-5879.	1.8	114
128	Prognostic Value of Vascular Endothelial Growth Factor Tumor Tissue Content of Colorectal Cancer. <i>Oncology</i> , 2005, 69, 145-153.	0.9	36
129	Oxidant Stress and Platelet Activation in Hypercholesterolemia. <i>Antioxidants and Redox Signaling</i> , 2004, 6, 747-756.	2.5	48
130	Soluble CD40 Ligand Plasma Levels in Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 610-614.	3.2	62
131	Platelet activation in type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1282-1291.	1.9	380
132	Inflammation, insulin resistance, and obesity. <i>Current Atherosclerosis Reports</i> , 2004, 6, 424-431.	2.0	120
133	Prognostic value of soluble P-selectin levels in colorectal cancer. <i>International Journal of Cancer</i> , 2004, 111, 404-408.	2.3	37
134	Correlation between tumor necrosis factor-alpha and d-dimer levels in non-small cell lung cancer patients. <i>Lung Cancer</i> , 2004, 44, 303-310.	0.9	23
135	Absolute neutrophil counts and fibrinogen levels as an aid in the early diagnosis of acute myocardial infarction. <i>Acta Cardiologica</i> , 2004, 59, 135-140.	0.3	4
136	In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 853-854.	1.9	6
137	Enhanced Interleukin-1 β in Hypercholesterolemia. <i>Circulation</i> , 2003, 108, 1673-1675.	1.6	37
138	Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. <i>Current Vascular Pharmacology</i> , 2003, 1, 157-169.	0.8	64
139	Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. <i>Journal of Investigative Medicine</i> , 2003, 51, 295-300.	0.7	75
140	Association between Serum Carcinoembryonic Antigen and Endothelial Cell Adhesion Molecules in Colorectal Cancer. <i>Oncology</i> , 2003, 65, 132-138.	0.9	16
141	Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. <i>Thrombosis and Haemostasis</i> , 2003, 89, 177-184.	1.8	42
142	Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. <i>Journal of Investigative Medicine</i> , 2003, 51, 295.	0.7	35
143	Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. <i>International Journal of Biological Markers</i> , 2003, 18, 21-27.	0.7	25
144	Tumor necrosis factor-alpha and myocardial function in patients with myotonic dystrophy type 1. <i>Journal of the Neurological Sciences</i> , 2002, 201, 59-64.	0.3	14

#	ARTICLE	IF	CITATIONS
145	Involvement of CD3 in platelet activation. A novel association with Fcγ receptor. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002, 1583, 297-304.	1.2	21
146	Reply to: Lipoprotein (a) and chronic obstructive pulmonary disease. <i>Atherosclerosis</i> , 2001, 155, 525-526.	0.4	1
147	Effects of mud-pack treatment on plasma cytokine and soluble adhesion molecule levels in healthy volunteers. <i>Clinica Chimica Acta</i> , 2001, 314, 209-214.	0.5	16
148	Rebuttal to Circulating IL-6 Levels in Chronic Obstructive Pulmonary Disease. <i>Thrombosis and Haemostasis</i> , 2001, 85, 373-373.	1.8	2
149	Increased Soluble P-Selectin Levels in Hepatitis C Virus-Related Chronic Hepatitis. <i>Journal of Investigative Medicine</i> , 2001, 49, 407-412.	0.7	20
150	Effects of Isolated Limb Perfusion With Tumor Necrosis Factor- α on Circulating Levels of Proinflammatory Cytokines. <i>Journal of Immunotherapy</i> , 2001, 24, 354-362.	1.2	5
151	Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 9-19.	1.1	35
152	Is Soluble P-selectin Determination a More Reliable Marker of In Vivo Platelet Activation than CD62P Flow Cytometric Analysis?. <i>Thrombosis and Haemostasis</i> , 1999, 81, 472-473.	1.8	32
153	Soluble P-Selectin and Proinflammatory Cytokines in Patients with Polygenic Type IIa Hypercholesterolemia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 277-285.	0.5	9
154	Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. <i>Atherosclerosis</i> , 1999, 147, 249-252.	0.4	44
155	Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients. <i>Platelets</i> , 1998, 9, 309-314.	1.1	4
156	Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. <i>Platelets</i> , 1997, 8, 255-260.	1.1	9
157	Ganglioside Content of Human Platelets – Differences in Resting and Activated Platelets. <i>Thrombosis and Haemostasis</i> , 1997, 77, 548-554.	1.8	18
158	POTENTIAL USEFULNESS OF ANTIPLATELET AGENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. <i>Thrombosis Research</i> , 1996, 84, 279-284.	0.8	2
159	Effects of storage on in vitro platelet responses: Comparison of ACD and Na citrate anticoagulated samples. , 1996, 10, 134-139.		10
160	Acid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 138-140.	0.9	22
161	CA 72-4 Serum Marker – A New Tool in the Management of Carcinoma Patients. <i>Cancer Investigation</i> , 1995, 13, 227-238.	0.6	45
162	Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions. <i>European Journal of Cancer</i> , 1995, 31, 79-84.	1.3	14

#	ARTICLE	IF	CITATIONS
163	Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 1183-1191.	0.7	9
164	In Vivo Thrombin Generation and Platelet Hyperactivity in Patients with Chronic Obstructive Pulmonary Disease. <i>Platelets</i> , 1994, 5, 276-278.	1.1	6
165	Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease. <i>Thrombosis and Haemostasis</i> , 1994, 72, 343-346.	1.8	62
166	Platelet proaggregating activity of human colorectal tumour cell lines does not correlate with the degree of differentiation. <i>European Journal of Cancer</i> , 1993, 29, 1028-1033.	1.3	3
167	Evaluation of the clinical utility of platelet aggregation studies in the long-term follow-up of patients with atherosclerotic vascular disease. <i>Journal of Clinical Laboratory Analysis</i> , 1992, 6, 257-263.	0.9	10
168	In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1991, 18, 395-401.	0.3	6
169	Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1991, 18, 383-387.	0.3	2
170	Blood Leukotrienes in Headache: Correlation With Platelet Activity. <i>Headache</i> , 1991, 31, 409-414.	1.8	24
171	Ca 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. <i>International Journal of Cancer</i> , 1990, 46, 445-451.	2.3	32
172	Assay for the detection of anti-idiotypic antibodies to monoclonal antibody b72.3. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 465-473.	0.9	6
173	Ca 72-4 radioimmunoassay for the detection of the tag-72 carcinoma-associated antigen in serum of patients. <i>Journal of Clinical Laboratory Analysis</i> , 1989, 3, 360-369.	0.9	64
174	A multiparametric index of platelet in vitro aggregation in cerebrovascular disease. <i>Italian Journal of Neurological Sciences</i> , 1987, 8, 561-566.	0.1	3